Table 1 Clinical, radiological, and CSF data at first episode of LETM
Demographic data | Whole cohort | Non-relapsing patients in the first 18 months | Relapsing patients in the first 18 months |
|---|---|---|---|
n | 53 | 41 | 12 |
Female, n (%) | 28 (52.8) | 22 (54%) | 6 (50%) |
Age at onset, years median (range) | 38 (16.5–80) | 38 (16.5–80) | 43.2 (26–65) |
Follow-up, years median (range) | 3.94 (1.5–12) | 2.88 (1.5–11.3) | 5.98 (3.91–12) |
EDSS at nadir, median (range) | 6 (1–8.5) | 6.5 (1–8.5) | 5.25 (1–8.5) |
Spinal cord MRI dataa | |||
· Cervical only | 7 | 6 | 1 |
· Thoracic only | 18 | 14 | 4 |
· Lumbar only | 3 | 3 | 0 |
· Cervical and thoracic | 14 | 10 | 4 |
· Cervical, thoracic and lumbar | 7 | 6 | 1 |
· Thoracic and lumbar | 4 | 2 | 2 |
· Cervical involvement, n (%) | 28 (53%) | 22 (54%) | 6 (50%) |
· Thoracic involvement, n (%) | 43 (81%) | 32 (78%) | 11 (92%) |
· Lumbar involvement, n (%) | 14 (26%) | 11 (27%) | 3 (25%) |
Laboratory datab | |||
CSF OCB, n = 50, n (%) | 15 (30%) | 12/38 (32%) | 3/12 (25%) |
CSF pleocytosis (> 5 cells/mm3), n = 52, n (%) | 28 (54%) | 22/40 (55%) | 6/12 (50%) |
Proteinorachy (> 0.5 g/L), n = 51, n (%) | 24 (47%) | 18/39 (46%) | 6/12 (50%) |